Quick Facts / Company Snapshot
- Company Name: Eurofins Scientific SE
- Year Founded: 1987
- Founder: Dr Gilles Martin
- Headquarters: Luxembourg
- Total Employees: Over 65,000 staff
- Global Reach: 59 countries
- Network Size: More than 950 laboratories
- 2025 Total Revenues: €7,296.1 million
- 2025 Organic Revenue Growth: 4.1%
- 2025 Adjusted EBITDA: €1,641 million
- 2025 Reported EBITDA: €1,561 million
- 2025 Free Cash Flow to the Firm: €876 million
- 2025 Basic Earnings Per Share (EPS): €2.31
- 2025 Proposed Dividend: €0.72 per share
- CEO and Chairman: Dr Gilles Martin
- Business Segments: Europe, North America, Rest of the World
- Areas of Activity: BioPharma, Diagnostic Services & Products, Consumer & Technology Products Testing, Life
- Total Tests Performed: Over 450 million tests per year
- Testing Methods Portfolio: More than 200,000 analytical methods
- Stock Index: CAC 40
Company overview
Eurofins Scientific SE is a globally recognized leader in the analytical testing and laboratory services industry, operating with a mission of “Testing for Life.” The organization has grown from a single laboratory established in 1987 into a vast, decentralized network comprising more than 950 laboratories across 59 countries. This extensive physical footprint is fully supported by an exceptionally skilled workforce of over 65,000 dedicated professionals who continuously push the frontiers of scientific advancement.
- Testing volume: The network companies perform more than 450 million tests annually.
- Analytical portfolio: The organization possesses a highly specialized portfolio of over 200,000 analytical testing methods.
- Core purpose: The enterprise aims to contribute to a safer and healthier world by verifying the safety, identity, composition, authenticity, and purity of biological substances.
The core services delivered by the enterprise are fundamentally designed to protect human health and the environment. By meticulously applying scientific principles, the organization ensures that the food consumed, the air breathed, the medicines administered, and the everyday products utilized meet the most stringent safety standards. The enterprise operates under a highly decentralized structure, empowering entrepreneurial leaders at the laboratory level to foster business agility and localized customer responsiveness while still leveraging the massive economies of scale provided by the global network.
The enterprise maintains leadership positions across multiple niches, notably in food, environment, pharmaceutical, and cosmetic product testing. Its long-term strategic approach prioritizes sustained investments in state-of-the-art laboratory infrastructure and proprietary digital solutions. By actively building a hub-and-spoke laboratory architecture, the organization unlocks significant cost advantages and accelerates turnaround times, continuously generating sustainable value for all its stakeholders.
Business segments
The operations of the enterprise are structured geographically to reflect the localized nature of regulatory requirements while unlocking synergies through an integrated hub-and-spoke network. The financial performance is strictly monitored across three primary geographic segments.
- Total 2025 Revenues: €7,296.1 million across all geographic segments.
- Overall Organic Growth: The consolidated group achieved an organic growth rate of 3.7% for the year 2025.
Europe
The European segment represents the historical foundation and the largest operational territory for the enterprise, characterized by highly stringent regulatory environments and dense laboratory networks.
- 2025 Revenues: €3,829.0 million.
- Percentage of Total Revenues: 52.4%.
- Organic Growth: Achieved a 3.3% organic growth rate in 2025.
- Reported EBITDA: Generated €667.6 million in reported EBITDA.
Growth within this segment was solid across Food and Feed Testing, supported by both pricing attainment and volume expansion. The Environment Testing business continued to benefit from expanding European Union directives concerning wastewater and hazardous substances. Furthermore, the Clinical Diagnostics business in Europe expanded significantly due to the strategic acquisition of Synlab’s clinical diagnostics operations in Spain. Profitability in the region improved due to strict volume growth and personnel cost management, successfully absorbing the impact of routine clinical testing tariff cuts in France.
North America
The North American segment acts as a massive growth engine, driven by significant consumer demand, vast infrastructure investments, and complex environmental regulations.
- 2025 Revenues: €2,684.8 million.
- Percentage of Total Revenues: 36.8%.
- Organic Growth: Delivered an organic growth rate of 2.8%.
- Reported EBITDA: Reached €747.9 million, showcasing exceptional profitability.
This segment saw robust growth in Food and Feed Testing driven by market share gains and high demand for product design services. The Environment Testing division maintained its market leadership in PFAS testing, successfully executing mid-single-digit organic growth. While some BioPharma testing activities experienced constrained demand due to early clinical trial terminations, the BioPharma Product Testing division remained highly solid, benefiting from the integration of Infinity Laboratories to form the largest GMP microbiology testing network on the continent.
Rest of the World
The Rest of the World segment encompasses rapidly developing markets across Asia-Pacific, Latin America, and the Middle East, representing high future growth potential for the enterprise.
- 2025 Revenues: €782.3 million.
- Percentage of Total Revenues: 10.7%.
- Organic Growth: Achieved an outstanding 9.0% organic growth rate.
- Reported EBITDA: Recorded €189.4 million with a margin of 24.2%.
Growth in this division was heavily fueled by double-digit expansion in Food and Feed testing across Australia, China, and Southeast Asia. The Pacific region saw high single-digit growth in Environment Testing, supported by strategic acquisitions in Japan and Korea. The segment delivered 250 basis points of year-over-year EBITDA margin expansion, driven by increasing productivity, lower building costs, and stringent input cost management, proving highly accretive to the overall group margin.
History and evolution
The origins of the enterprise trace back to 1987 when it was founded by Dr Gilles Martin.
- Foundational breakthrough: The company began with a single entrepreneur, three employees, and one laboratory to market a patented analytical method.
- Initial technology: This original technology was used to accurately verify the origin and purity of food and beverages, successfully identifying sophisticated fraud undetectable by other means.
- Strategic expansion: Building on this unique capability, the organization expanded through multiple phases, continually adding a vast range of bioanalytical technologies to serve broader industries.
- Modern scale: Today, the enterprise operates over 950 laboratories and employs over 65,000 staff, having transformed into the definitive global leader in Testing for Life.
Over the past decade, the enterprise has executed a massive strategic transformation by developing a one-of-a-kind ‘hub and spoke’ laboratory infrastructure. By consolidating smaller, less efficient sites into large, high-throughput Centres of Excellence, the organization has structurally reduced costs and vastly improved service delivery times, cementing its competitive advantage for decades to come.
Products and services
The enterprise delivers an extraordinarily comprehensive portfolio of testing, inspection, and certification services grouped into primary end-market categories.
- Total 2025 Revenues: €7,296.1 million.
Life (Food, Feed, Agro, and Environment Testing)
This area focuses on safeguarding the fundamental elements of human existence by ensuring the safety and sustainability of the environment and the global food supply chain.
- 2025 Revenues: €3,043 million.
- Percentage of Total Revenues: 42%.
- Scope: Includes 130,000 analytical methods assessing food purity, water testing, air emissions, and soil contamination.
Services range from detecting persistent organic pollutants and microplastics in water to verifying the genetic modification of agricultural products.
BioPharma
The BioPharma activities span the complete product development cycle, from initial compound discovery to commercial release.
- 2025 Revenues: €2,062 million.
- Percentage of Total Revenues: 28%.
- Scope: Encompasses drug discovery, preclinical development, contract manufacturing (CDMO), and genomics.
This division provides essential outsourced research and testing services to the world’s largest pharmaceutical companies, ensuring rapid and safe drug development.
Diagnostic Services & Products
This service line contributes directly to patient care through advanced clinical diagnostics and specialized testing equipment.
- 2025 Revenues: €1,496 million.
- Percentage of Total Revenues: 21%.
- Scope: Includes specialized clinical testing (oncology, genetics, infectious diseases) and In Vitro Diagnostics (IVD) solutions.
The division provides highly specialized techniques for diagnosis and prognosis, alongside manufacturing clinical testing kits through Gold Standard Diagnostics.
Consumer & Technology Products Testing
This division ensures that everyday consumer goods meet stringent global safety, regulatory, and sustainability standards.
- 2025 Revenues: €695 million.
- Percentage of Total Revenues: 10%.
- Scope: Covers testing for cosmetics, textiles, toys, and electronic wireless devices.
By verifying chemical composition, flammability, and performance, this division protects brand integrity and accelerates global market access for manufacturers.
Brand portfolio
While the enterprise primarily utilizes the overarching “Eurofins” brand to project its global scale, it successfully integrates specialized brands and technologies to dominate high-growth testing niches.
- M&A Execution: The organization closed 40 transactions in 2025 for a total investment of €261 million.
Synlab (Spanish Clinical Diagnostics Operations)
Acquired in March 2025, this integration massively expands the clinical diagnostics footprint in Southern Europe.
- Market impact: Provided €132 million in annual revenues and added roughly 1,200 staff to the network.
- Strategic fit: Strongly complements the existing operations led by Eurofins Megalab, specializing in anatomical pathology and hospital laboratory management.
Gold Standard Diagnostics
Operating as the In Vitro Diagnostics (IVD) arm of the enterprise, this brand provides critical diagnostic technologies and instruments.
- Market impact: Vertically integrates key testing systems, ensuring the supply of in-house consumables and advanced PCR/ELISA assay kits.
- Strategic fit: Secures the supply chain for bioanalytical testing in food, feed, and clinical industries globally.
DiscoveryOne™
This brand represents the integrated drug discovery solution offered by the Eurofins Pharma Discovery Services network.
- Market impact: Provides comprehensive project-managed programs utilizing over 4,500 drug discovery products.
- Strategic fit: Seamlessly connects high-throughput screening, medicinal chemistry, and safety pharmacology to accelerate client research.
Professional Scientific Services® (PSS)
PSS is an award-winning insourcing service model tailored for biopharmaceutical clients.
- Market impact: Provides dedicated Eurofins personnel to manage laboratory operations directly at the client’s facility.
- Strategic fit: Removes headcount and co-employment concerns for pharmaceutical companies while maintaining strict testing compliance.
Geographical presence
The enterprise operates a pervasive and highly decentralized infrastructure that spans multiple continents, ensuring absolute proximity to clients and the rapid processing of highly sensitive testing samples.
- Total Global Locations: More than 950 laboratories.
- Global Workforce: Over 65,000 employees across 59 countries.
- Total Property Portfolio: 1,878,000 m² of net floor area at the end of 2025.
Europe
Europe functions as the core structural base for the organization, housing the highest density of specialized competence centers.
- 2025 Revenues: €3,829.0 million.
- Physical footprint: 390 laboratories employing roughly 37,300 staff.
- Strategic focus: The region is heavily focused on expanding the clinical diagnostics footprint (such as the Synlab acquisition in Spain) and managing large-scale public health screening initiatives.
North America
North America represents a highly profitable and rapidly consolidating market, specifically for BioPharma and Environment Testing.
- 2025 Revenues: €2,684.8 million.
- Physical footprint: 210 laboratories employing approximately 14,800 staff.
- Strategic focus: The region finalized a massive building and renovation cycle in 2025, deploying state-of-the-art facilities in Houston, Sacramento, and Denver to capture specialized PFAS and bioanalytical demand.
Asia / Pacific
This region acts as a massive growth driver, capturing the expanding supply chain, manufacturing, and environmental testing markets.
- 2025 Revenues: Included in the €782.3 million Rest of the World segment.
- Physical footprint: 150 laboratories employing around 12,400 staff.
- Strategic focus: The region is experiencing aggressive growth in food testing and is actively constructing a new state-of-the-art environment testing laboratory in Brisbane ahead of the 2032 Olympics.
South America & Africa
These developing markets provide critical growth opportunities, specifically in the agricultural and mining sectors.
- Physical footprint: 20 laboratories in South America (c. 1,100 employees) and 2 laboratories in Africa (c. 100 employees).
- Strategic focus: Operations in Brazil continue to show resilient growth in Food and Feed testing, while environmental capacities are continuously optimized.
Financial performance analysis
The 2025 fiscal year demonstrated the immense resilience and underlying operating leverage of the Eurofins network, delivering robust margin expansion despite challenging macroeconomic conditions.
- Consolidated Revenues: Reached €7,296.1 million, an increase of 5.0% year-over-year.
- Organic Growth Rate: The group delivered a solid 4.1% organic growth rate (adjusted for working days).
- Basic EPS: Basic earnings per share surged 24% to €2.31, up from €1.87 in 2024.
The organization successfully delivered an Adjusted EBITDA margin of 24.3% on mature scope revenues. The total Adjusted EBITDA reached €1,641 million. This exceptional profitability was achieved by unlocking the scale of the hub-and-spoke network, ensuring strict cost discipline, and driving value from the maturing start-up laboratory programs. The enterprise maintained an incredibly strong balance sheet, allocating €541 million to share repurchases while keeping its leverage ratio at a comfortable 2.2x.
Profit and loss analysis
The consolidated income statement for the year ended 31 December 2025 highlights the successful conversion of top-line revenue into highly tangible net profit.
Consolidated Income Statement
| (In € millions) | 2025 Reported Results | 2024 Reported Results |
| Revenues | 7,296.1 | 6,951.0 |
| Operating costs, net | -5,735.1 | -5,511.6 |
| EBITDA | 1,561.0 | 1,439.4 |
| Depreciation and amortisation | -629.5 | -596.9 |
| EBITAS | 931.5 | 842.5 |
| Share-based payment and acquisition expenses | -138.1 | -138.3 |
| Gain/loss on disposal of subsidiaries | -8.9 | -23.6 |
| EBIT | 784.5 | 680.5 |
| Finance income | 35.2 | 24.2 |
| Finance costs | -165.8 | -151.2 |
| Share of profit of associates | 0.3 | 1.0 |
| Profit before income taxes | 654.1 | 554.6 |
| Income tax expense | -181.1 | -149.1 |
| Net profit for the year | 473.0 | 405.5 |
The operating costs strictly reflect the personnel-intensive nature of the scientific services provided. The improvement in the reported EBITDA margin to 21.4% highlights the diminishing drag of Separately Disclosed Items (SDIs), which decreased by 29% year-over-year as the massive investments in start-up laboratories began achieving profitability.
Balance sheet analysis
The balance sheet perfectly reflects the group’s highly capital-efficient operations and strategic real estate acquisitions.
Consolidated Balance Sheet
| (In € millions) | 31 December 2025 | 31 December 2024 |
| Non-current assets | ||
| Property, plant and equipment | 2,762.9 | 2,559.8 |
| Goodwill | 4,657.2 | 4,840.7 |
| Other intangible assets | 689.9 | 787.8 |
| Investments in associates | 5.3 | 5.9 |
| Non-current financial assets | 100.2 | 111.5 |
| Deferred tax assets | 116.4 | 130.3 |
| Total non-current assets | 8,331.9 | 8,436.2 |
| Current assets | ||
| Inventories | 139.3 | 141.9 |
| Trade receivables | 1,097.0 | 1,094.3 |
| Contract assets | 324.3 | 306.2 |
| Prepaid expenses and other current assets | 182.5 | 192.2 |
| Current income tax assets | 116.2 | 101.8 |
| Derivative financial instruments assets | 3.0 | 2.0 |
| Cash and cash equivalents | 791.2 | 613.9 |
| Total current assets | 2,653.5 | 2,452.2 |
| Total assets | 10,985.4 | 10,888.4 |
| Shareholders’ equity | ||
| Total attributable to owners of the Company | 4,543.3 | 5,339.0 |
| Non-controlling interests | 33.4 | 45.8 |
| Total shareholders’ equity | 4,576.7 | 5,384.7 |
| Non-current liabilities | ||
| Borrowings | 3,705.3 | 3,131.5 |
| Deferred tax liabilities | 121.1 | 109.5 |
| Amounts due for business acquisitions | 49.8 | 62.8 |
| Employee benefit obligations | 64.2 | 66.4 |
| Provisions | 28.9 | 23.2 |
| Total non-current liabilities | 3,979.0 | 3,393.4 |
| Current liabilities | ||
| Borrowings | 726.7 | 478.8 |
| Trade accounts payable | 678.1 | 645.9 |
| Contract liabilities | 217.4 | 195.9 |
| Other current liabilities | 644.6 | 621.0 |
| Total current liabilities | 2,429.6 | 2,110.2 |
| Total liabilities and shareholders’ equity | 10,985.4 | 10,888.4 |
Working capital management was exceptionally strong, driving the working capital ratio down to just 2.7% of Group revenues. The net debt stood at €3,641 million, translating to a highly manageable leverage ratio of 2.2x, validating the group’s investment grade ratings from Moody’s and Fitch.
Cash flow analysis
The enterprise acts as a high-growth cash compounder, converting laboratory operations into immense free cash flow utilized for M&A and structural expansion.
Consolidated Cash Flow Statement
| (In € millions) | 2025 | 2024 |
| Net cash provided by operating activities | 1,398.9 | 1,318.9 |
| Purchase of property, plant and equipment | -461.7 | -453.6 |
| Purchase, capitalisation of intangible assets | -74.9 | -74.8 |
| Proceeds from sale of property/equipment | 14.2 | 10.2 |
| Net capex | -522.4 | -518.2 |
| Free Cash Flow to the Firm | 876.5 | 800.6 |
| Acquisition of subsidiaries, net | -261.4 | -343.4 |
| Purchase of property from related parties | -298.2 | – |
| Net cash used in investing activities | -1,076.2 | -846.5 |
| Purchase of treasury shares, net of gains | -541.3 | -271.9 |
| Proceeds from borrowings | 1,221.8 | 118.0 |
| Repayment of borrowings | -310.9 | -477.7 |
| Repayment of lease liabilities | -194.0 | -192.4 |
| Dividends paid to shareholders | -109.8 | -98.0 |
| Net cash (used in) / provided by financing | -102.5 | -1,089.6 |
| Cash and cash equivalents at end of year | 791.2 | 613.9 |
The operating cash flow increased by 6% year-over-year, leading to a massive €876.5 million Free Cash Flow to the Firm. Excluding strategic real estate purchases, the free cash flow exceeded €1.07 billion. This incredible cash generation easily funded €261 million in bolt-on acquisitions and heavily supported shareholder returns through a €541 million net share repurchase program.
Board of directors and leadership team
The Board of Directors governs the strategic direction, risk management, and overall corporate governance of the enterprise. The leadership structure ensures a sharp focus on continuous scientific innovation and unyielding financial discipline.
- Dr Gilles Martin: Chairman of the Board of Directors and Chief Executive Officer. Dr Martin is the visionary founder of the company, leading its expansion from a single laboratory in 1987 into a global testing behemoth.
- Valerie Hanote: Member of the Board of Directors.
- Yves-Loic Martin: Member of the Board of Directors.
- Pascal Rakovsky: Independent Member of the Board of Directors.
- Evie Roos: Independent Member of the Board of Directors.
- Stuart Anderson: Independent Member of the Board of Directors.
The executive management team comprises highly specialized directors who oversee the distinct global business lines and geographical regions, empowering the decentralized laboratories to act with total entrepreneurial agility.
Subsidiaries, associates, joint ventures
Eurofins operates as a vast holding structure, controlling an immense portfolio of specialized subsidiaries globally. In 2025 alone, the enterprise acquired 25 new legal entities and executed 15 asset acquisitions.
- Synlab (Spanish Operations): Acquired in early 2025 for its comprehensive clinical diagnostics and anatomical pathology network in Spain.
- Eurofins Viracor: A leading North American specialty clinical trial and infectious disease testing laboratory.
- Eurofins Megalab: Anchoring the clinical diagnostics and hospital laboratory management sector in Spain.
- Eurofins DiscoverX: Expanding its footprint in California to provide products supporting drug discovery.
- Infinity Laboratories: Acquired in 2024 and fully integrated into the BioPharma Product Testing network in 2025, creating the largest microbiology testing network in North America.
The group also actively divested a small loss-making clinical testing business in the Netherlands to optimize its capital return structure.
Physical properties (offices, plants, factories, etc.)
The physical footprint of the enterprise is incredibly dense, designed to provide localized support while leveraging global hub testing efficiencies.
- Global Facilities: The network operates more than 950 distinct laboratories spanning 59 countries.
- Total Net Floor Area: The operational footprint reached 1,878,000 m² by the end of 2025.
- Capital Expenditures: The group deployed €522 million in net capex to modernize and expand this massive infrastructure.
In 2025, Eurofins executed a strategic transaction to acquire 31 related-party owned strategic campuses across eight countries, bringing 239,000 m² of net floor area under direct corporate ownership. Major physical facility completions included the renovation of an 8,800 m² bioanalytical campus in Lenexa, Kansas, the acquisition of a 6,173 m² genetics testing hub in Fairfield, Ohio, and a new automated Agro testing laboratory in Jena, Germany.
Segment-wise performance
The operational execution in 2025 delivered highly robust performance metrics across the geographic divisions.
- Rest of the World: Showcased the highest growth metrics with 9.0% organic growth. The segment achieved a phenomenal 24.2% EBITDA margin, supported by immense demand for Food Testing in Asia.
- North America: Generated €2,684.8 million in revenue with a 2.8% organic growth rate. Strict cost control and productivity gains expanded the EBITDA margin to a highly lucrative 27.9%.
- Europe: Delivered €3,829.0 million in revenue with 3.3% organic growth. Profitability increased to an EBITDA margin of 17.4%, successfully navigating routine testing tariff cuts in France.
Founders
The enterprise was founded in 1987 by Dr Gilles Martin, who utilized a groundbreaking, patented analytical method to test the authenticity of food products. His entrepreneurial vision and unwavering commitment to scientific excellence propelled the transformation of a small regional laboratory into the ultimate global authority in bioanalytical testing.
Shareholding pattern
The capital structure is heavily anchored by the founding family, ensuring long-term strategic stability and consistent value creation.
- Martin Family: Through direct shareholdings and indirectly via Analytical Bioventures SCA, the Martin family holds 35.2% of the total share capital and commands 69.1% of the theoretical voting rights.
- Free Float: Represents 61.7% of the total shares and 30.9% of the voting rights.
- Treasury Shares: The company actively executes share buybacks, holding a designated portion of its own capital to enhance shareholder returns.
Parent
Eurofins Scientific SE acts as the ultimate parent holding company of the global enterprise. It governs and consolidates the vast international network of testing subsidiaries without being subordinate to any larger corporate parent, ensuring total independence and impartiality.
Investments and capital expenditure plans
Capital allocation is executed with disciplined precision, balancing the need for laboratory modernization with aggressive acquisition targets.
- Capital Expenditure (Capex): Net operating capex stood at €328 million in 2025. Total net capex (including the strategic purchase of owned sites) reached €522 million.
- Mergers & Acquisitions (M&A): The group successfully deployed €261 million in 2025 across 40 transactions, generating €286 million in pro-forma revenues.
- Strategic Priorities: For 2026 and 2027, the enterprise targets a net operating capex of roughly €400 million per year, alongside deploying approximately €200 million annually to transition from leasing to owning its strategic properties.
Future strategy
The corporate trajectory is dictated by a long-term strategy designed to cement Eurofins as the global leader in Testing for Life.
- Organic Growth Targets: The group aims to achieve mid-single-digit organic growth in 2026, targeting a long-term average organic growth objective of 6.5% annually.
- Margin Expansion: The objective is to push the Adjusted EBITDA margin up to 24% by 2027 by fully completing the hub-and-spoke network and replacing legacy systems with next-generation LIMS solutions.
- Acquisition Ambitions: The enterprise intends to execute highly targeted bolt-on M&A, securing an average of €250 million in annualized revenues acquired per year.
- Digital Transformation: Implement total laboratory digitalization and leverage proprietary Artificial Intelligence to optimize testing accuracy and completely automate the reporting processes.
Key strengths
The organization leverages an array of formidable structural advantages that secure its position as the ultimate bioanalytical authority.
- Unmatched Scale: A network of over 950 laboratories allows the group to process 450 million tests annually, generating immense economies of scale.
- Technological Supremacy: A proprietary portfolio of over 200,000 analytical methods and vast biological databases creates a massive barrier to entry.
- Entrepreneurial Agility: The decentralized corporate structure guarantees localized customer responsiveness while utilizing the financial power of the global holding entity.
- Financial Resilience: An incredibly cash-generative operating model ensures structural flexibility, perfectly highlighted by the 56% free cash flow conversion rate.
Key challenges and risks
Operating in an incredibly complex and strictly regulated global environment exposes the enterprise to distinct operational risks.
- Regulatory Complexity: Navigating shifting policies from the FDA, EPA, and European equivalents requires massive compliance oversight. Changes in clinical reimbursement tariffs (like those seen in France) can temporarily compress margins.
- Technological Disruption: The rapid pace of biotech innovation requires perpetual capital investment in new testing frameworks to avoid equipment obsolescence.
- Cybersecurity Risk: The widespread connectivity of LIMS systems and vast repositories of client biological data creates immense vulnerability to cyberattacks, demanding strict, costly IT security protocols.
- Professional Liability: The consequences of issuing an incorrect analytical report could lead to catastrophic product recalls for clients, resulting in intense legal and reputational damage to the Eurofins brand.
Conclusion and strategic outlook
In 2025, Eurofins brilliantly demonstrated the sheer structural power of its global laboratory network by delivering highly robust organic growth, exceptional margin expansion, and a massive surge in free cash flow. The enterprise has successfully utilized its unparalleled technical expertise and vast geographic footprint to dominate the definitive megatrends of the modern era: the necessity for untainted food and water, the aggressive acceleration of biopharmaceutical development, and the expansion of highly personalized clinical diagnostics.
By consistently investing in its proprietary digital systems, fully realizing the cost advantages of its hub-and-spoke infrastructure, and relentlessly executing targeted acquisitions, Eurofins is perfectly positioned to capture future market share. Supported by an incredibly disciplined financial structure and an unwavering commitment to scientific integrity, the enterprise is exceptionally well-equipped to achieve its highly ambitious 2027 margin targets, continuing to define the absolute gold standard in the global Testing for Life industry.
FAQ section
What is the core business of Eurofins?
Eurofins is a global leader in analytical testing and laboratory services, operating under the mission “Testing for Life” to verify the safety, authenticity, and purity of food, environment, pharmaceutical, and clinical products.
How large is the company’s global network?
The enterprise operates a vast network comprising more than 950 laboratories and facilities situated across 59 countries.
How many people does the organization employ?
The company relies on a dedicated global workforce of over 65,000 professionals.
What were the total revenues for 2025?
The group generated a total reported revenue of €7,296.1 million in 2025, achieving a solid organic growth rate of 4.1%.
What is the hub-and-spoke model used by the company?
The hub-and-spoke model involves routing specialized or high-volume testing from smaller local laboratories (spokes) to massive, highly automated regional Competence Centres (hubs) to drastically reduce costs and improve turnaround times.
How does the company allocate its capital?
The group deploys capital toward organic infrastructure expansion (targeting €400 million annually), aggressive real estate acquisition, strategic bolt-on M&A, and rewarding shareholders through dividends and share buybacks.
What are the primary business segments?
Operations are primarily divided geographically into Europe, North America, and the Rest of the World, serving industries such as BioPharma, Food & Feed, Environment, and Clinical Diagnostics.
What was the most significant acquisition in 2025?
The acquisition of Synlab’s Spanish clinical diagnostics operations, which provided €132 million in annual revenues and significantly bolstered Eurofins’ anatomical pathology network in Southern Europe.
What is the enterprise’s mid-term financial target?
The organization aims to drive its Adjusted EBITDA margin to 24% by 2027 through digitalization and the full operational realization of its laboratory network.
Who holds the majority of the voting rights?
The Martin family, including Founder and CEO Dr Gilles Martin, controls 69.1% of the total voting rights.
Official Site: https://www.eurofins.com
Source: Content on FirmsWorld.com is based on publicly available corporate filings, regulatory disclosures, annual reports, SEC 10-K filings, investor relations materials, and, where applicable, direct communications with the company.
